Recent weeks have brought encouraging news for the inherited retinal disease (IRD) community, with significant progress reported in both clinical trials and regulatory designations for novel therapies. These developments offer renewed hope for patients and families affected by these debilitating conditions.

Belite Bio's Tinlarebant Shows Further Promise for Stargardt Disease

Belite Bio has announced additional positive secondary endpoint data from its Phase 3 DRAGON trial for tinlarebant in Stargardt Disease Type 1 (STGD1). These findings were presented at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. Tinlarebant is an oral therapy designed to reduce the accumulation of toxic vitamin A-derived by-products, known as bisretinoids, which are implicated in the progression of STGD1.

The DRAGON trial, which enrolled 104 subjects globally, previously met its primary efficacy endpoint, demonstrating a statistically significant 35.7% reduction in the growth rate of retinal lesions compared to placebo. The newly reported secondary endpoint data further strengthens these results. Specifically, quantitative autofluorescence (qAF), a marker for bisretinoid accumulation, showed a marked difference between treatment groups. At month 25, subjects receiving tinlarebant maintained stable or slightly decreased qAF values (approximately 2% decrease from baseline), while placebo-treated subjects experienced an approximate 20% increase from baseline. This suggests that tinlarebant effectively stabilizes or reduces the toxic buildup that drives the disease.

Tinlarebant has been well-tolerated throughout the trial and has already received multiple regulatory designations, including Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations in the U.S., as well as Orphan Drug designation in Europe, Japan, and Switzerland. Belite Bio has also completed its New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA), positioning tinlarebant as a potential first-approved treatment for STGD1.

Atsena Therapeutics Gains EMA Orphan Designations for Gene Therapies

In another significant development, Atsena Therapeutics has received Orphan Designation from the European Medicines Agency (EMA) for two of its clinical-stage gene therapy candidates: ATSN-101 for Leber congenital amaurosis 1 (LCA1) and ATSN-201 for X-linked retinoschisis (XLRS).

EMA Orphan Designation is granted to therapies addressing rare, life-threatening, or chronically debilitating conditions, providing benefits such as reduced regulatory fees, clinical protocol assistance, research grants, and up to 10 years of market exclusivity in the EU. This designation underscores the significant unmet medical needs for patients with LCA1 and XLRS, who currently lack approved treatment options.

ATSN-101, an investigational gene therapy for LCA1, has shown durable and clinically significant improvements in vision in a completed Phase 1/2 clinical trial, with a favorable safety profile. Atsena plans to initiate a global pivotal Phase 3 clinical trial for ATSN-101 later this year.

ATSN-201 is being developed for XLRS, a genetic condition caused by mutations in the RS1 gene, leading to progressive vision loss due to retinal layer splitting. The pivotal Phase 3 LIGHTHOUSE trial for ATSN-201 is currently enrolling rapidly, with the first patient dosed in June 2026. Previous Phase 1/2 data for ATSN-201 indicated improvements in retinal structure and visual function, with no drug-related serious adverse events. ATSN-201 uses a proprietary AAV capsid engineered to spread effectively across the central retina.

Both ATSN-101 and ATSN-201 had previously received multiple designations from the U.S. FDA, including Orphan Drug, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) designations.

A Future with More Options

These advancements represent crucial steps forward in the quest to provide effective treatments for inherited retinal diseases. The positive data for tinlarebant in Stargardt disease brings an oral therapy closer to approval, potentially offering a convenient and impactful option for patients. Meanwhile, Atsena Therapeutics' progress with its gene therapy candidates, bolstered by EMA Orphan Designations, highlights the growing potential of genetic medicines to address the root causes of conditions like LCA1 and XLRS. The continued momentum in both small molecule and gene therapy approaches signals a hopeful future for individuals living with IRDs, promising a landscape with more therapeutic choices and improved quality of life.